Apolipoprotein E-derived peptides reduce CNS inflammation: Implications for therapy of neurological disease

Acta Neurologica Scandinavica

Volumn 114, Issue SUPPL. 185, 2006, Pages 15-20

  Laskowitz, D T ^a   Fillit, H ^b   Yeung, N ^c   Toku, K ^a   Vitek, M P ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Alzheimers Drug Discovery Foundation   (United States)

^c Optimal Screening Vehicles Division   (United States)

Author keywords

Apolipoprotein E; Inflammation; Neuroprotection; Peptides

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; COG133 PEPTIDE; ISOPROTEIN; PEPTIDE; UNCLASSIFIED DRUG; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM INFLAMMATION; DRUG PENETRATION; GENETIC SUSCEPTIBILITY; GLIA; HISTOLOGY; INFLAMMATION; MOLECULAR MIMICRY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; RECEPTOR BINDING; TRAUMATIC BRAIN INJURY; HUMAN; NEUROGENIC INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BLOOD-BRAIN BARRIER; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; NERVOUS SYSTEM DISEASES; NEUROGENIC INFLAMMATION; NEUROGLIA; PEPTIDE FRAGMENTS;

EID: 33745751979     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00680.x     Document Type: Article

References (43)

1. WEISGRABER KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249-302.
2. STOLL G, MEULLER HW, TRAPP BD, GRIFFIN JW. Oligodendrocytes but not astrocytes express apolipoprotein E after injury of rat optic nerve. Glia 1989;2:170-6.
3. CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
4. FLEMING LM, WEISGRABER KH, STRITTMATTER WJ, TRONCOSO JC, JOHNSON GV. Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins. Exp Neurol 1996;138:252-60.
5. GALLO G, WISNIEWSKI T, CHOI-MIURA NH, GHISO J, FRANGIONE B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994;145:526-30.
6. STRITTMATTER WJ, SAUNDERS AM, GOEDERT M et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A 1994;91:11183-6.
7. STRITTMATTER WJ, SAUNDERS AM, SCHMECHEL D et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81.
8. ALBERTS MJ, GRAFFAGNINO C, MCCLENNY C et al. ApoE genotype and survival from intracerebral haemorrhage. Lancet 1995;346:575.
9. FRIEDMAN G, FROOM P, SAZBON L et al. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999;52:244-8.
10. MO MC, MUIR KW, WEIR CJ et al. The apolipoprotein E epsilon4 allele and outcome in cerebrovascular disease. Stroke 1998;29:1882-7.
11. SORBI S, NACMIAS B, PIACENTINI S et al. ApoE as a prognostic factor for post-traumatic coma. Nat Med 1995;1:852.
12. TARDIFF BE, NEWMAN MF, SAUNDERS AM et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg 1997;64:715-20.
13. TEASDALE GM, NICOLL JA, MURRAY G, FIDDES M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997;350:1069-71.
14. PIEDRAHITA JA, ZHANG SH, HAGAMAN JR, OLIVER PM, MAEDA N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 1992;89:4471-5.
15. LASKOWITZ DT, SHENG H, BART RD, JOYNER KA, ROSES AD, WARNER DS. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 1997;17:753-8.
16. BART RD, SHENG H, LASKOWITZ DT, PEARLSTEIN RD, WARNER DS. Regional CBF in apolipoprotein E-deficient and wild type mice during focal cerebral ischemia. Neuroreport 1998;9:2615-20.
17. HORSBURGH K, KELLY S, MCCULLOCH J, HIGGINS GA, ROSES AD, NICOLL JA. Increased neuronal damage in apolipoprotein E-deficient mice following global ischaemia. Neuroreport 1999;10:837-41.
18. SHENG H, LASKOWITZ DT, MACKENSEN GB, KUDO M, PEARLSTEIN RD, WARNER DS. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse. Stroke 1999;30:1118-24.
19. HORSBURGH K, MCCULLOCH J, NILSEN M et al. Intraventricular infusion of apolipoprotein E ameliorates acute neuronal damage after global cerebral ischemia in mice. J Cereb Blood Flow Metab 2000;20:458-62.
20. WELLONS JC, PINEDA J, MASEY G, PEARLSTEIN RD, WARNER DS, LASKOWITZ DT. Intra-cerebroventricular infusion of human recombinant apolipoprotein E3 reduces global ischemic brain injury in apolipoprotein E deficient mice. Neurosurgery 2000;47:2000.
21. COLTON CA, BROWN CM, CZAPIGA M, VITEK MP. Apolipoprotein-E allele-specific regulation of nitric oxide production. Ann N Y Acad Sci 2002;962:212-25.
22. LASKOWITZ DT, THEKDI AD, THEKDI SD et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001;167:74-85.
23. AVILA EM, HOLDSWORTH G, SASAKI N, JACKSON RL, HARMONY JA. Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells. J Biol Chem 1982;257:5900-9.
24. COLTON CA, BROWN CM, COOK D et al. APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging 2002;23:777-85.
25. COLTON CA, NEEDHAM LK, BROWN C et al. APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol 2004;147:62-7.
26. CURTISS LK, EDGINGTON TS. The biologic activity of the immunoregulatory lipoprotein, LDL-In is independent of its free fatty acid content. J Immunol 1981;126:1382-6.
27. DE BONT N, NETEA MG, DEMACKER PN et al. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999;40:680-5.
28. LASKOWITZ DT, LEE DM, SCHMECHEL D, STAATS HF. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 2000;41:613-20.
29. LYNCH JR, MORGAN D, MANCE J, MATTHEW WD, LASKOWITZ DT. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 2001;114:107-13.
30. LYNCH JR, TANG W, WANG H et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003;278:48529-33.
31. LINTON MF, GISH R, HUBL ST et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991;88:270-81.
32. ANDERSEN OM, PETERSEN HH. New light on a long-known protein family. Chembiochem 2003;4:1137-46.
33. AONO M, BENNETT ER, KIM KS et al. Protective effect of apolipoprotein E-mimetic peptides on N-methyl-D-aspartate excitotoxicity in primary rat neuronal-glial cell cultures. Neuroscience 2003;116:437-45.
34. MISRA UK, ADLAKHA CL, GAWDI G, MCMILLIAN MK, PIZZO SV, LASKOWITZ DT. Apolipoprotein E and mimetic peptide initiate a calcium-dependent signaling response in macrophages. J Leukoc Biol 2001;70:677-83.
35. GURUNATH R, BALARAM P. Incorporation of a potentially helix breaking D-Phe-Pro sequence into the center of a right handed 16 residue peptide helix. Biochem Biophys Res Commun 1994;202:241-5.
36. MARSHALL GR, HODGKIN EE, LANGS DA, SMITH GD, ZABROCKI J, LEPLAWY MT. Factors governing helical preference of peptides containing multiple alpha,alpha-dialkyl amino acids. Proc Natl Acad Sci U S A 1990;87:487-91.
37. LYNCH JR, WANG H, MACE B et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005;192:109-16.
38. MCADOO JD, WARNER DS, GOLDBERG RN, VITEK MP, PEARLSTEIN R, LASKOWITZ DT. Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. Neurosci Lett 2005;381:305-8.
39. BARGER SW, HARMON AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997;388:878-81.
40. HU J, LADU MJ, VAN ELDIK LJ. Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation. J Neurochem 1998;71:1626-34.
41. LASKOWITZ DT, GOEL S, BENNETT ER, MATTHEW WD. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 1997;76:70-4.
42. LASKOWITZ DT, MATTHEW WD, BENNETT ER et al. Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. Neuroreport 1998;9:615-8.
43. CROY JE, BRANDON T, KOMIVES EA. Two apolipoprotein E mimetic peptides, ApoE(130-149) and ApoE(141-155)2, bind to LRP1. Biochemistry 2004;43:7328-35.